| Literature DB >> 30156606 |
Erivelton Alessandro do Nascimento1,2, Christiane Cigagna Wiefels Reis2, Fernanda Baptista Ribeiro3, Christiane Rodrigues Alves2, Eduardo Nani Silva3, Mario Luiz Ribeiro3, Claudio Tinoco Mesquita2.
Abstract
BACKGROUND: Heart failure (HF) affects more than 5 million individuals in the United States, with more than 1 million hospital admissions per year. Cardiac resynchronization therapy (CRT) can benefit patients with advanced HF and prolonged QRS. A significant percentage of patients, however, does not respond to CRT. Electrical dyssynchrony isolated might not be a good predictor of response, and the last left ventricular (LV) segment to contract can influence the response.Entities:
Mesh:
Year: 2018 PMID: 30156606 PMCID: PMC6199515 DOI: 10.5935/abc.20180159
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
General baseline characteristics of the patients submitted to cardiac resynchronization device implantation
| Demographic characteristics | N or mean ± SD |
|---|---|
| Total of patients | 15 |
| Age (years) | 63.21 ± 7.7 |
| Body mass index (kg/m2) | 26.92 ± 5.4 |
| Male sex | 4 |
| Diabetes mellitus | 6 |
| Hypertension | 9 |
| Dyslipidemia | 8 |
| Smoking | 0 |
| Previous coronary artery disease | 7 |
| Previous infarction | 7 |
| Coronary artery bypass grafting | 2 |
| Percutaneous coronary intervention | 0 |
| NYHA functional class II | 1 |
| NYHA functional class III | 7 |
| NYHA functional class IV | 5 |
| Beta-blocker | 13 |
| Angiotensin-converting-enzyme inhibitor | 8 |
| Angiotensin-receptor blocker | 7 |
| Acetylsalicylic acid | 2 |
| Diuretics | 8 |
| Statin | 5 |
| Aldosterone antagonist | 8 |
| Digoxin | 4 |
Figure 1Comparison of the mean score of the Minnesota Living with Heart Failure Questionnaire before and after cardiac resynchronization therapy, using Student t test.
Figure 2Gated myocardial perfusion SPECT with analysis of ventricular synchronism in a patient with dilated cardiomyopathy and left bundle-branch block, showing marked dyssynchrony with HBW of 245° and SD of 97°.
Figure 3Correlation between SD and HBW before cardiac resynchronization therapy (R2: 0.78)
Figure 4Distribution of the mean pre- and post-cardiac resynchronization therapy left ventricular ejection fraction according to clinical response to implantation. Pre-CRT LVEF PRE: pre-cardiac resynchronization therapy left ventricular ejection fraction; Post-CRT LVEF: post-cardiac resynchronization therapy left ventricular ejection fraction; RESPOND: responder group; NONRESPOND: non-responder group. (Student t test).
Figure 5Distribution of the mean pre-cardiac resynchronization therapy SD and HBW according to clinical response. SD: standard deviation; HBW: histogram bandwidth (Student t test).
Figure 6Response to cardiac resynchronization therapy according to the left ventricular lead implantation site. Post Lat - posterolateral region; Post Sep - posteroseptal region.
Figure 7Fluoroscopy during implantation of the cardiac resynchronization device with left ventricular lead implanted in the maximal delay site determined on GATED SPECT.